Placebo Part A
Sponsors
Dompé Farmaceutici S.p.A, AstraZeneca, ImmunAbs Inc.
Conditions
HealthyHealthy ParticipantsMyasthenia Gravis
Phase 1
Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers
CompletedNCT01744704
Start: 2012-07-31End: 2013-03-31Updated: 2024-04-19
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
CompletedNCT06122714
Start: 2023-11-07End: 2024-12-04Updated: 2024-12-13
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
RecruitingNCT07250750
Start: 2026-02-05End: 2028-06-01Target: 96Updated: 2026-02-11